New Data Show Upadacitinib's Superiority Over Adalimumab for RA Treatment Recent findings indicate that Upadacitinib outperforms Adalimumab in patients with insufficient response to TNF inhibitors, showing promise in RA treatment.

New Data Show Upadacitinib's Superiority Over Adalimumab for RA Treatment #United_States #North_Chicago #RA_Treatment #Upadacitinib #Adalimumab

Spyre Therapeutics Unveils Promising First Quarter 2025 Results with Major Corporate Updates Spyre Therapeutics shares encouraging results from Q1 2025, highlighting progress in clinical trials for IBD and RA while strengthening its financial position.

Spyre Therapeutics Unveils Promising First Quarter 2025 Results with Major Corporate Updates #USA #Spyre_Therapeutics #Waltham #IBD_Research #RA_Treatment